Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Potential breakthrough in osteoarthritis treatment

Rat experiments could see new pain relieving injections

Pain relieving injections for osteoarthritis sufferers (OA) which avoid the risk of hyperthermia and potentially eliminate the need for surgery, have been discovered in experiments using rats.

At the moment people experiencing the severe pain associated with OA are offered pain relieving drugs such as steroid injections and anti-inflammatory drugs, which reduce inflammation.
Severe side effects, however, limit their use.

Previous clinical trials to block pain receptor TRPV1 failed as they had adverse effects on body temperature, resulting in hyperthermia.

Now researchers from The University of Nottingham have experimented with 176 rats to see whether this side effect can be avoided by an injection directly to the joint.

Dr Sara Kelly, a lecturer in neuroscience at the university, and one of the lead researchers on the project, said: “Using a model of human osteoarthritis pain we wanted to investigate if by blocking these receptors locally within the diseased joint, could we reduce the pain caused by osteoarthritis, without the side effect of hyperthermia — and the answer is yes.
 
“Osteoarthritis is a very common disease and the pain it causes is severe and can last a life time.

"A lot of patients who suffer with osteoarthritis are elderly and it would be better if we could treat their pain by giving them a drug, rather than putting them through a major surgical procedure like a joint replacement.

"The annual cost of joint replacement to the NHS is close to £200 million, which is another reason to look for a more effective solution.
 
“By targeting the joint directly, we did not see the side effect of hyperthermia, which is thought to be generated outside of the joint at the level of abdominal organs."

Clinical trials in human patients will now need to be undertaken.

In this country alone, osteoarthritis affects more than eight million people. An ageing population and growing obesity epidemic will see this figure rise.
 
Prof Alan Silman, medical director of Arthritis Research UK, which funded the research, said: “We desperately need new approaches to treating the pain of osteoarthritis.

"For some years this particular pathway has shown potential as a means by which osteoarthritic pain may be transmitted, but until now attempts at blocking this pathway have caused unacceptable side-effects.
 
“This research seems to suggest it might be possible to overcome this and to provide a novel and effective approach to targeting osteoarthritis.”

To view the full research paper — Increased Function of Pronociceptive TRPV1 at the Level of the Joint in a Rat Model of Osteoarthritis Pain — click here
 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.